Drug Profile
YIV 906
Alternative Names: KD018; PHY-906; YIV-906Latest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator PhytoCeutica
- Developer Kadmon Corporation; PhytoCeutica; Yale University; Yiviva
- Class Chemoprotectants
- Mechanism of Action Acetylcholinesterase modulators; Cyclo-oxygenase 2 inhibitors; Cytochrome P 450 enzyme system inhibitors; Metalloprotease inhibitors; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; Opioid delta receptor antagonists; P-glycoprotein inhibitors; Tachykinin receptor antagonists; Wnt signalling pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer; Liver cancer
- Phase I/II Pancreatic cancer
- Clinical Phase Unknown Rectal cancer
- Preclinical Inflammatory bowel diseases; Irritable bowel syndrome; Malignant melanoma; Non-small cell lung cancer
- Discontinued Gastrointestinal disorders
Most Recent Events
- 05 Feb 2024 Yiviva completes enrolment in its phase II CALM trial for Liver cancer in USA, China, Hong Kong, and Taiwan (NCT04000737)
- 11 Oct 2023 Clinical trial in Rectal cancer (Neoadjuvant therapy) is still ongoing in USA (PO) (Yiviva pipeline, October 2023)
- 11 Oct 2023 Preclinical trials in Inflammatory bowel diseases in USA (PO), prior to October 2023 (Yiviva pipeline, October 2023)